Thonburi Medical Centre PCL

Thonburi Medical Centre PCL maintains a strong liquidity position, with a current ratio of 4.43 and cash and equivalents amounting to 249.35 million THB, indicating a robust ability to meet short-term obligations. The company's liquidity is further supported by a low debt-to-equity ratio of 0.01, suggesting minimal reliance on debt financing and a conservative capital structure.

In terms of profitability, the company's return on equity (ROE) of 4.29% and return on assets (ROA) of 3.41% are below the industry median for healthcare facilities and services, which typically report ROE and ROA in the 6-8% and 4-5% ranges, respectively. This suggests that the company is underperforming relative to its peers in terms of capital efficiency and asset utilization.

The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification reported. This lack of diversification may expose the company to higher operational and market risks, particularly in the event of a regional downturn or regulatory change.

Looking ahead, the company's revenue is projected to grow at a modest pace, with the current fiscal year expected to show a slight increase in revenue compared to the previous year. However, the growth trajectory is not expected to accelerate significantly in the next fiscal year, as the company's capital expenditure remains negative at -11.18 million THB, indicating a focus on cost management rather than expansion.

The company's risk profile is characterized by low liquidity and dilution risks, with no immediate filing-based flags detected. The low dilution risk is further supported by the absence of significant share issuance activity in the recent financial statements. However, the company's price-to-earnings ratio of 51.67 and price-to-book ratio of 2.22 suggest that the stock is currently trading at a premium relative to its earnings and book value, which may indicate investor optimism or overvaluation.

Recent events, including the latest financial filings and transcripts, do not indicate any material changes in the company's operations or strategic direction. The company continues to focus on maintaining its financial stability and operational efficiency, as reflected in its conservative capital structure and strong liquidity position.

Net income surged 33.2% year-over-year to 140.6 million THB, demonstrating strong recent profitability growth.

The company maintains a negligible debt-to-equity ratio of 0.01, significantly lower than the cohort median of 0.32.

Cash conversion ratio of 3.21 ranks above the 75th percentile, indicating superior cash generation efficiency.

Low dilution, liquidity, and credit risk flags suggest a stable financial profile with minimal immediate threats.

Four-year revenue CAGR is negative at -2.6%, indicating a long-term contraction in sales volume.

Return on equity of 4.29% falls below the healthcare cohort median of 4.56%, suggesting lower capital efficiency.

Free cash flow decreased 5.0% year-over-year to 96.4 million THB, reducing liquidity generation capacity.

Four-year net income CAGR is negative at -2.0%, reflecting inconsistent earnings performance over time.

Revenue THB 1.14B, +11,2% YoY; Operating income +9,3% YoY.

• ▍Revenue THB 1.14B, +11,2% YoY
• ▍Operating income +9,3% YoY
• ▍Net income +8,3% YoY
• ▍Free cash flow −24,7% YoY
• ▍Net margin 13.4%